Navigation Links
Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
Date:6/28/2009

ch slowly progress and eventually lead to a largely irreversible loss of lung function. COPD is currently the fourth most common cause of death and by 2030 is predicted to become the third most common cause of death and the fourth most important disability causing illness. The total financial burden of lung disease in Europe amounts to nearly EUR102 billion with COPD contributing almost one half of this figure. Around three-quarters of patients with advanced COPD are unable to perform normal everyday activities. The market for COPD drug therapy was estimated to be worth around $5.7 billion in 2007 with a compound average growth rate of 19% over the preceding 5 years. Further significant growth can be anticipated as a result of better diagnosis and treatment and the introduction of high value new products.

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

About Vectura

Vectura Group plc is a product-focused Group that develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD); a growing market that is currently estimated to be worth $20 billion. Vectura also develops products for other lung pathologies and non-respiratory diseases.

Vectura has eight products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, some of which
'/>"/>

SOURCE Sosei Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 29 Asahi Kasei Medical Co., Ltd. is pleased to ... MF-SL, its new range of microfilters for bioprocessing applications. Designed specifically ... biopharmaceutical manufacturers to improve the efficiency and effectiveness of their protein ... , ...
... IRIDEX Corporation (Nasdaq: IRIX ) today announced that it will release its ... August 5, 2010 .  In conjunction with the release, the Company will ... Eastern Time on Thursday, August 5, 2010 ... , , ...
Cached Medicine Technology:Launch of BioOptimalâ„¢ MF-SL Microfilters for Bioprocessing 2IRIDEX Announces Second Quarter 2010 Conference Call and Release Date 2
(Date:4/18/2014)... University School of Medicine researchers have been awarded two-year ... Novo Nordisk announced this month. Of the 110 initial ... Biologics Science Forum Program, only four projects were funded, ... They are Jonathan Powell, M.D., Ph.D.; G. William Wong, ... Powell, a professor of oncology, will use his $500,000 ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... bog outshines 19 commonly eaten fruits for the ... latest,Agricultural Research Service Report from USDA, containing the ... foods, shows cranberries,score among the highest of all ... The report includes antioxidant values for a ...
... Children with autism have normal-size heads at birth but ... of age, a period that precedes the onset of ... disorder, according to new research from the University of ... aberrant growth is present in children who have the ...
... Conn.A protein has been found that influences the response of ... such as occurs during a heart attack, a team of ... This finding may present a new therapeutic approach to treating ... The protein, macrophage migration inhibitory factor (MIF), was found to ...
... Bay Park to be the focus of this inaugural ... ... An unclimbed mountain near Mount Abbe,in the northern reaches of Alaska,s ... Expedition for Cancer Research, a quest,sponsored by Fred Hutchinson Cancer Research ...
... 30 Prime Therapeutics (Prime) has,joined the Center ... from,the pharmacy benefit manager (PBM) industry. The Center ... collaborates with leading,organizations to develop and promote innovative ... the health of employees. Members,of the Center represent ...
... estrogen 55 times faster , , WEDNESDAY, Jan. 30 (HealthDay ... release a potentially harmful chemical 55 times faster than ... found in the plastics that make up water bottles, ... acts as an environmental estrogen and can disrupt the ...
Cached Medicine News:Health News:Cranberries' Antioxidant Level Tops List in USDA Report 2Health News:Cranberries' Antioxidant Level Tops List in USDA Report 3Health News:Accelerated head growth can predict autism before behavioral symptoms start 2Health News:Hutchinson Center Announces First Unclimbed Mountain to be Tackled by Big Expedition for Cancer Research 2Health News:Prime Therapeutics Becomes First PBM to Join the Center for Health Value Innovation 2Health News:Heating Plastic Bottles Releases Potentially Harmful Chemical 2Health News:Heating Plastic Bottles Releases Potentially Harmful Chemical 3
... is an automated, multiparametric immunoassay ... device stores the calibration in ... the cost-per-patient result. Plus, with ... ease of use and uni/bi-directional ...
Alpha prime immunoassay system features unsurpassed quality of results, full automation of EIA tests for microplate applications, complete walk-away, up to 18 different assays per run, photometric an...
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: